Analytical performance of an immunoassay to measure proenkephalin

Leslie J. Donato, Jeffrey W. Meeusen, John C Lieske, Deborah Bergmann, Andrea Sparwaßer, Allan S Jaffe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Endogenous opioids, enkephalins, are known to increase with acute kidney injury. Since the mature pentapeptides are unstable, we evaluated the performance of an assay that measures proenkephalin 119–159 (PENK), a stable peptide formed concomitantly with mature enkephalins. Methods: PENK assay performance was evaluated on two microtiterplate/chemiluminescence sandwich immunoassay formats that required 18 or 1 h incubation times. PENK concentration was measured in plasma from healthy individuals to establish a reference interval and in patients with varied levels of kidney function and comorbidities to assess the association with measured glomerular filtration rate (mGFR) using iothalamate clearance. Results: Assay performance characteristics in plasma were similar between the assay formats. Limit of quantitation was 26.0 pmol/L (CV = 20%) for the 1 h assay and 17.3 pmol/L (CV = 3%) for the 18 h assay. Measurable ranges were 26–1540 pmol/L (1 h assay) and 18–2300 pmol/L (18 h assay). PENK concentrations are stable in plasma stored ambient to 10 days, refrigerated to at least 15 days, and frozen to at least 90 days. Results were comparable in paired SST serum and EDTA plasma. Age and sex were not associated with PENK concentrations in healthy individuals (reference interval: 36–97.5 pmol/L). Plasma PENK concentration correlated with mGFR. In a multivariate model PENK concentration, age, sex and transplant status were significant predictors of mGFR, and 49% of predicted GFR values fell within 30% of the mGFR. Conclusions: Both assay formats are accurate and precise for measuring clinically relevant PENK concentrations. The association of PENK concentration with mGFR is influenced by gender, age, and history of kidney transplantation. Future studies will determine if blood PENK can be used clinically to estimate GFR and/or detect AKI.

Original languageEnglish (US)
JournalClinical Biochemistry
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Immunoassay
Assays
Glomerular Filtration Rate
Plasmas
Enkephalins
Iothalamic Acid
proenkephalin
Association reactions
Transplants
Chemiluminescence
Luminescence
Acute Kidney Injury
Edetic Acid
Kidney Transplantation
Opioid Analgesics
Comorbidity
Blood
Kidney
Peptides
Serum

Keywords

  • Assay validation
  • Biomarkers
  • Enkephalin
  • penKid
  • Pro-enkephalin
  • Proenkephalin

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Analytical performance of an immunoassay to measure proenkephalin. / Donato, Leslie J.; Meeusen, Jeffrey W.; Lieske, John C; Bergmann, Deborah; Sparwaßer, Andrea; Jaffe, Allan S.

In: Clinical Biochemistry, 01.01.2018.

Research output: Contribution to journalArticle

Donato, Leslie J. ; Meeusen, Jeffrey W. ; Lieske, John C ; Bergmann, Deborah ; Sparwaßer, Andrea ; Jaffe, Allan S. / Analytical performance of an immunoassay to measure proenkephalin. In: Clinical Biochemistry. 2018.
@article{ed03349c7f844c78ad8e02be4853df7e,
title = "Analytical performance of an immunoassay to measure proenkephalin",
abstract = "Background: Endogenous opioids, enkephalins, are known to increase with acute kidney injury. Since the mature pentapeptides are unstable, we evaluated the performance of an assay that measures proenkephalin 119–159 (PENK), a stable peptide formed concomitantly with mature enkephalins. Methods: PENK assay performance was evaluated on two microtiterplate/chemiluminescence sandwich immunoassay formats that required 18 or 1 h incubation times. PENK concentration was measured in plasma from healthy individuals to establish a reference interval and in patients with varied levels of kidney function and comorbidities to assess the association with measured glomerular filtration rate (mGFR) using iothalamate clearance. Results: Assay performance characteristics in plasma were similar between the assay formats. Limit of quantitation was 26.0 pmol/L (CV = 20{\%}) for the 1 h assay and 17.3 pmol/L (CV = 3{\%}) for the 18 h assay. Measurable ranges were 26–1540 pmol/L (1 h assay) and 18–2300 pmol/L (18 h assay). PENK concentrations are stable in plasma stored ambient to 10 days, refrigerated to at least 15 days, and frozen to at least 90 days. Results were comparable in paired SST serum and EDTA plasma. Age and sex were not associated with PENK concentrations in healthy individuals (reference interval: 36–97.5 pmol/L). Plasma PENK concentration correlated with mGFR. In a multivariate model PENK concentration, age, sex and transplant status were significant predictors of mGFR, and 49{\%} of predicted GFR values fell within 30{\%} of the mGFR. Conclusions: Both assay formats are accurate and precise for measuring clinically relevant PENK concentrations. The association of PENK concentration with mGFR is influenced by gender, age, and history of kidney transplantation. Future studies will determine if blood PENK can be used clinically to estimate GFR and/or detect AKI.",
keywords = "Assay validation, Biomarkers, Enkephalin, penKid, Pro-enkephalin, Proenkephalin",
author = "Donato, {Leslie J.} and Meeusen, {Jeffrey W.} and Lieske, {John C} and Deborah Bergmann and Andrea Sparwa{\ss}er and Jaffe, {Allan S}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.clinbiochem.2018.05.010",
language = "English (US)",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Analytical performance of an immunoassay to measure proenkephalin

AU - Donato, Leslie J.

AU - Meeusen, Jeffrey W.

AU - Lieske, John C

AU - Bergmann, Deborah

AU - Sparwaßer, Andrea

AU - Jaffe, Allan S

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Endogenous opioids, enkephalins, are known to increase with acute kidney injury. Since the mature pentapeptides are unstable, we evaluated the performance of an assay that measures proenkephalin 119–159 (PENK), a stable peptide formed concomitantly with mature enkephalins. Methods: PENK assay performance was evaluated on two microtiterplate/chemiluminescence sandwich immunoassay formats that required 18 or 1 h incubation times. PENK concentration was measured in plasma from healthy individuals to establish a reference interval and in patients with varied levels of kidney function and comorbidities to assess the association with measured glomerular filtration rate (mGFR) using iothalamate clearance. Results: Assay performance characteristics in plasma were similar between the assay formats. Limit of quantitation was 26.0 pmol/L (CV = 20%) for the 1 h assay and 17.3 pmol/L (CV = 3%) for the 18 h assay. Measurable ranges were 26–1540 pmol/L (1 h assay) and 18–2300 pmol/L (18 h assay). PENK concentrations are stable in plasma stored ambient to 10 days, refrigerated to at least 15 days, and frozen to at least 90 days. Results were comparable in paired SST serum and EDTA plasma. Age and sex were not associated with PENK concentrations in healthy individuals (reference interval: 36–97.5 pmol/L). Plasma PENK concentration correlated with mGFR. In a multivariate model PENK concentration, age, sex and transplant status were significant predictors of mGFR, and 49% of predicted GFR values fell within 30% of the mGFR. Conclusions: Both assay formats are accurate and precise for measuring clinically relevant PENK concentrations. The association of PENK concentration with mGFR is influenced by gender, age, and history of kidney transplantation. Future studies will determine if blood PENK can be used clinically to estimate GFR and/or detect AKI.

AB - Background: Endogenous opioids, enkephalins, are known to increase with acute kidney injury. Since the mature pentapeptides are unstable, we evaluated the performance of an assay that measures proenkephalin 119–159 (PENK), a stable peptide formed concomitantly with mature enkephalins. Methods: PENK assay performance was evaluated on two microtiterplate/chemiluminescence sandwich immunoassay formats that required 18 or 1 h incubation times. PENK concentration was measured in plasma from healthy individuals to establish a reference interval and in patients with varied levels of kidney function and comorbidities to assess the association with measured glomerular filtration rate (mGFR) using iothalamate clearance. Results: Assay performance characteristics in plasma were similar between the assay formats. Limit of quantitation was 26.0 pmol/L (CV = 20%) for the 1 h assay and 17.3 pmol/L (CV = 3%) for the 18 h assay. Measurable ranges were 26–1540 pmol/L (1 h assay) and 18–2300 pmol/L (18 h assay). PENK concentrations are stable in plasma stored ambient to 10 days, refrigerated to at least 15 days, and frozen to at least 90 days. Results were comparable in paired SST serum and EDTA plasma. Age and sex were not associated with PENK concentrations in healthy individuals (reference interval: 36–97.5 pmol/L). Plasma PENK concentration correlated with mGFR. In a multivariate model PENK concentration, age, sex and transplant status were significant predictors of mGFR, and 49% of predicted GFR values fell within 30% of the mGFR. Conclusions: Both assay formats are accurate and precise for measuring clinically relevant PENK concentrations. The association of PENK concentration with mGFR is influenced by gender, age, and history of kidney transplantation. Future studies will determine if blood PENK can be used clinically to estimate GFR and/or detect AKI.

KW - Assay validation

KW - Biomarkers

KW - Enkephalin

KW - penKid

KW - Pro-enkephalin

KW - Proenkephalin

UR - http://www.scopus.com/inward/record.url?scp=85047385386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047385386&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2018.05.010

DO - 10.1016/j.clinbiochem.2018.05.010

M3 - Article

C2 - 29782819

AN - SCOPUS:85047385386

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

ER -